What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Ivy Brain Tumor Center

Home
United States
Phoenix, AZ
Ivy Brain Tumor Center

The largest Phase 0 Clinical Trials Program for aggressive brain cancer.

In compliance with federal and state privacy laws, please do not include any private health information in any message you send us through this channel.

11/27/2025

Today, we're filled with gratitude. Happy Thanksgiving to our patients, families, donors, team, and partners. Your trust, generosity, dedication, and support mean the world to us. Wishing everyone a beautiful day filled with love, thanks, and cherished memories! 🦃

11/22/2025

It’s the last day to visit the Ivy Brain Tumor Center booth at SNO! 🧠💚
Stop by, say hello, and learn more about our work after a successful round of research poster presentations this week.

11/22/2025

This November, we're celebrating another milestone within our dedicated team! Join us in acknowledging another year of passion and commitment contributing to brain tumor research and patient care here at the Ivy Brain Tumor Center. Thank you for all you do! 💚

11/21/2025

Excited to share Ivy Brain Tumor Center’s latest research at SNO 2025! 🧠💚
Stop by our poster presentations to learn how we’re accelerating progress in brain tumor treatment and innovation.

11/21/2025

Ivy Friendsgiving! So much to thank our Ivy Brain Tumor Center family for. Feeling incredibly grateful for this amazing community. Wishing everyone a season filled with love and gratitude! ❤️

11/20/2025

Our Phase 0/1b clinical trial of Quisinostat is now open for patients with newly diagnosed and recurrent glioblastoma. Contact our Ivy Navigators to explore if this study may be right for you. Quisinostat is an investigational study drug.
🌐 https://bar.rw/3LSJQsU
☎️ 602-406-8605
✉️ Research@IvyBrainTumorCenter.org

11/18/2025

Exciting News!📢 The U.S. FDA has granted ODD to niraparib for the treatment of malignant glioma, including GBM. The designation is supported by the clinical trial interim data reported by the Ivy Brain Tumor Center at Barrow Neurological Institute. ODD is a special status granted by the FDA to medicines intended to treat, diagnose, or prevent rare diseases. This designation provides incentives such as regulatory support, tax credits, and potential market exclusivity to accelerate the development of treatments for patients with rare and life-threatening conditions.

Read here: https://www.ivybraintumorcenter.org/about/newsroom/news/phase-3-gliofocus-study-drug-niraparib-granted-orphan-drug-designation-by-u-s-fda-for-treatment-of-malignant-glioma-including-glioblastoma/

11/18/2025

We are immensely proud to congratulate two of the Ivy Center's very own, Dr. Erika Lewis and Maryam Gharehsheikhlou, PharmD., on receiving the prestigious BNF Fast Track Award!

11/14/2025

This week, the Ivy Brain Tumor Center team in collaboration with colleagues at Yale University, published our latest study in Neuro-Oncology (Oxford University Press/Society for Neuro-Oncology).

Led by Nader Sanai, MD, Roel G.W. Verhaak, PhD, and Shwetal Mehta, PhD with our Ivy Center team, the paper reports data from our Phase 0/1 trial evaluating PK/PD and single cell responses of ribociclib (CDK4/6 inhibitor) and everolimus (mTOR inhibitor) combination treatment in recurrent high-grade glioma.

Dr. Mehta illustrates the importance of the results and says, "the study shows that ribociclib reached the brain, while everolimus did not achieve pharmacologically meaningful levels and highlights the importance of tissue-based trials for developing brain penetrant drugs in neuro-oncology."

Read here: https://bar.rw/43XL648

11/13/2025

At the Ivy Brain Tumor Center, we believe in the power of kindness. How are you showing yours today?

$Navigating a relapsed or refractory primary central nervous system lymphoma? At the Ivy Center, we are now enrolling a c...$

11/12/2025

Navigating a relapsed or refractory primary central nervous system lymphoma? At the Ivy Center, we are now enrolling a clinical trial studying anti-cancer activity of Emavusertib (CA-4948).
Determine your eligibility today: https://bar.rw/4pnvdwn
☎️: 602-406-8605

11/10/2025

Want the inside scoop on brain tumor research, inspiring patient journeys, and upcoming community events? Get it all delivered straight to your inbox! Sign up now: ➡️https://bar.rw/3JV2Juz

Address

2910 North Third Avenue
Phoenix, AZ
85013

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Telephone

+16024066489

Website

http://www.ivybraintumorcenter.org/

Alerts

Be the first to know and let us send you an email when Ivy Brain Tumor Center posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Ivy Brain Tumor Center:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Practice
Claim ownership or report listing

Featured

Ahwatukee Psychology
11011 S 48th Street, Ste 106

Want your practice to be the top-listed Clinic in Phoenix?